This paradoxical observation is in contrast to another study investigating CDK9 expression in patients with de novo pancreatic adenocarcinoma tumors, which showed that high CDK9 expression has worse clinical outcome [21] as well as its current investigation as a therapeutic target for cancer treatment [22–25]. This evidence concerns the gene CDK9 and cancer.